Gracell Reports Positive Data from Trial of Off-the Shelf CAR-T Candidate

Gracell Biotech, a Suzhou cell therapy company, reported positive results from a China Phase I trial of its allogeneic CAR-T candidate. GC027 targets CD7. It was administered to adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) who had previously been treated with a median of six therapies. A single infusion of GC027 at one of three dosing levels produced a complete remission in all six patients. In the future, Gracell plans to test GC027 in global markets for T-All and other cancers as well. More details... Stock Symbol: (NDQQ: GRCL) Share this with colleagues: // //